Pfizer’s Begins Clinical Trials for Antiviral

September 22, 2020

Pfizer’s Begins Clinical Trials for Antiviral

Pfizer has initiated Phase 1 clinical tests of PF-07304814, a small molecule that could be used in the fight against SARS-CoV-2, which causes COVID-19. The drug targets the 3CL protease, an enzyme that allows the virus to multiply. If approved, PF-07304814 would be the first antiviral drug to target this protein. With 21 strategically located global depots, Yourway can fully support global trial needs around the world.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Global Clinical Supplies Group (GCSG)

October 14-16, 2025
Hungary, Budapest

Schedule a Meeting

Clinical Outsourcing Group (COG)

October 21-22, 2025
Burlingame, California

Schedule a Meeting

Media

Articles

Keeping trials on track: Prioritizing communication in decentralized trials

Open chat

Hello! How can I help you?